Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045618 | 0.86 | TPMT (0.49) | GAAALDH1A1KDM4ETPMTMAPT | |
| SCHEMBL8427153 | 0.81 | KDM4E (0.51) | GAAALDH1A1KDM4ETPMTMAPT | |
| SCHEMBL25218326 | 0.80 | KDM4E (0.49) | GAAALDH1A1KDM4EMAPTHTT | |
| SCHEMBL4119971 | 0.80 | ALDH1A1 (0.49) | GAAALDH1A1KDM4ETPMTMAPT | |
| SCHEMBL25514839 | 0.80 | KDM4E (0.39) | ALDH1A1KDM4EHPGDHTTMEN1 | |
| SCHEMBL31095594 | 0.80 | KDM4E (0.49) | GAAALDH1A1KDM4EMAPTHTT | |
| SCHEMBL1748528 | 0.79 | ALDH1A1 (0.41) | GAAALDH1A1KDM4ETPMTMAPT | |
| SCHEMBL7358999 | 0.79 | KDM4E (0.44) | GAAALDH1A1KDM4ETPMTNQO2 | |
| SCHEMBL4480747 | 0.79 | HSD17B10 (0.50) | GAAALDH1A1KDM4ETPMTMAPT | |
| SCHEMBL2101809 | 0.78 | CYP3A4 (0.50) | GAAALDH1A1KDM4ETPMTTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632845-B2 | 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol; inflammatory bowel disease; Crohn's disease; anticarcinogenic agents; anticholesterol agents; antilipemic agents; cardiovascular diorders; osteoporosis; A lzheimer's disease; fertility; antiarthritic agents | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20060217399-A1 | Phenyl quinolines and their use as estrogenic agents | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7084276-B2 | Phenyl quinolines and their use as estrogenic agents | WYETH (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1628961-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | Wyeth (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050009784-A1 | Phenyl quinolines and their use as estrogenic agents | WYETH | 2005-01-13 | — | — | US | disclosed |
| WO-2004103973-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | WYETH (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009784-A1 | Phenyl quinolines and their use as estrogenic agents | ESR1, GPER1, ESR2 | GAA 4471/4885ALDH1A1 904/4885KDM4E 638/4885 |
| US-20060217399-A1 | Phenyl quinolines and their use as estrogenic agents | ESR1, GPER1, ESR2 | GAA 4471/4885ALDH1A1 904/4885KDM4E 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.